Navigation Links
Glucagon in Medical Technology

Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568

... ISIS 325568 is an Antisense Drug Targeting glucagon Receptor for Treatment ... designed to selectively inhibit the production of glucagon receptor and has demonstrated improved glucose ... responsibilities over to our partner." ABOUT glucagon RECEPTOR (GCGR), TARGET OF ISIS 325568 ...

Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes

... type 2 diabetes by inhibiting production of the glucagon receptor (GCGR). GCGR is a receptor that binds ... for future studies." ISIS 325568 Targets the glucagon Receptor (GCGR) glucagon is a hormone that opposes the action of insulin ...

One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function

... BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake ... elevated levels of blood sugar, inhibiting the release of a hormone called glucagon following meals, slowing the rate at which nutrients are absorbed into the ...

One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function

... BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake ... elevated levels of blood sugar, inhibiting the release of a hormone called glucagon following meals, slowing the rate at which nutrients are absorbed into the ...

Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009

... and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas ...

Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009

... and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas ...

Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly

... and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas ...

New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors

... on the human body as the natural hormone somatostatin. However, octreotide is even more potent than somatostatin at inhibiting growth hormone, glucagon and insulin. Based on these attributes, octreotide has been used to treat symptoms associated with metastatic carcinoid tumors (flushing and ...

Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback

... and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas ...

Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes

... response to food and regulate glucose balance, primarily by stimulating glucose-dependent insulin secretion. In addition, GLP-1 suppresses pancreatic glucagon secretion and subsequent liver glucose production, enhances glucose disposal, slows gastric emptying, and elicits satiety, a feeling of fullness. ...

RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors

... on the human body as the natural hormone somatostatin. However, octreotide is even more potent than somatostatin at inhibiting growth hormone, glucagon and insulin. Based on these attributes, octreotide has been used to treat the diarrhea and flushing associated with carcinoid syndrome. The active ...

After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008

... and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas ...

Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight

... and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas ...

Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss

... and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas ...

DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia

... Patent Protects Very Low Dose glucagon ahead of Phase 2 Clinical Trials in 2008 SAN FRANCISCO, Jan. 8 /PRNewswire/ -- DiObex, Inc., a privately ...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

... pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading ... JANUVIA increases insulin release and decreases glucagon levels in the circulation in a ... levels of active GLP-1 and GIP, decreased glucagon concentrations, and increased responsiveness ...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

... for energy. GLP-1 also suppresses the release of glucagon from the pancreatic alpha cells, which, in turn, ... pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading ... JANUVIA increases insulin release and decreases glucagon levels in the circulation in a ...

PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing

... About PC-DAC(TM):Exendin-4 Exendin-4 is a Glucagon-like peptide-1 (GLP-1) homolog and an agonist for the GLP-1 receptor. Exendin-4 decreases glucagon and increases insulin secretion in a glucose-dependent manner. Exendin-4 may stimulate beta-cell proliferation, restore beta-cell sensitivity ...

Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for Heart Failure

... cells appeared as bud-like clusters resembling the islets of Langerhans and included the major islet cell types that produce the hormones insulin, glucagon and somatostatin. Upon exposure to increased concentrations of glucose, the islet-like clusters secreted insulin. When transplanted into diabetic ...

ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting

... Exendin-4, like Glucagon-like peptide-1 (GLP-1) is an insulinotropic peptide and an agonist for the GLP-1 receptor. Exendin-4 decreases glucagon and increases insulin secretion in a glucose-dependent manner. Exendin-4 may stimulate beta-cell proliferation, restore beta-cell sensitivity to ...

Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA

... has a favorable anti-diabetic role because it stimulates glucose dependent insulin secretion from the pancreas, slows gastric emptying and decreases glucagon secretion. Inhibitors to DPP-4 improve glycemic control in patients with type II diabetes by increasing the half-life of native GLP-1. DPP-4 is a ...

Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes

... class of drugs for the treatment of type 2 diabetes called incretin mimetics. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas ...

Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice

... the successful generation of MDIs from insulin-dependent type 1 and type 2 diabetics. These insulin producing islet-like clusters express insulin, glucagon and somatostatin characteristic hormones found in pancreatic islets and function in a glucose responsive manner. Dr. Winnier commented, "The ...
Other Contents
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.65 billion by ... 2014-2020 The near future will bring Biomedical ... each individual. These sensors can be set to trigger ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... 22, 2015 Research ... of the "Huawei Ascend Mate 7 Fingerprint ... their offering. Huawei,s technological choice for ... direction than Apple,s and Samsung,s one. The Ascend ... by Fingerprint Cards, a main actor in capacitive ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
(Date:7/3/2015)... ... July 03, 2015 , ... First Choice Emergency Room , ... N. Manzanares, MD as the new Medical Director of its Frisco facility. , “We ... our Frisco facility,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to ... the first sweetFrog store located in Mississippi. The premium frozen yogurt chain was listed ... The store, located at 104 Railroad Avenue, New Albany, MS 38652, will have a ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... structure retrofit project at the University of Minnesota, they knew it would save ... would also be an award-winning choice: the total energy savings after installation was ...
(Date:7/2/2015)... ... ... As Americans celebrate the Fourth of July outdoors this weekend, local physicians are warning ... UV Safety Month, and physicians at American Family Care and AFC Doctors Express urgent ... most skin cancers can be found early with regular skin exams. Physicians can give ...
(Date:7/2/2015)... ... 2015 , ... ActiveBunch.com recently launched as a social network created for people ... a lifestyle community, Active Bunch allows users to connect with like-minded fitness enthusiasts from ... discussions or group events. , The spokesperson for Active Bunch explained the idea ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:sweetfrog Opens First Location in Mississippi 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:Local Physicians Warn of Holiday Health Hazards 2Health News:Local Physicians Warn of Holiday Health Hazards 3Health News:Local Physicians Warn of Holiday Health Hazards 4Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2
Other TagsOther Tags